Pazopanib (Pz) as first line for metastatic renal carcinoma (mRC): Updated validation of the international metastatic renal-cell carcinoma database consortium prognostic model (IMRCC). The SPAZO study (SOGUG)

Data de publicación
2015Título da revista
EUROPEAN JOURNAL OF CANCER
Tipo de contido
Publicación de congreso
